11/14/2022 7:11:39 AM
CASI Pharmaceuticals Q3 Net Loss Narrows To $5.02 Mln From $10.2 Mln Last Year
9/7/2022 7:19:22 AM
CASI Pharma, BioInvent Announce Dosing First Patient In Phase 1 Study Of BI-1206 With Rituximab In China
8/12/2022 7:15:28 AM
CASI Pharmaceuticals Q2 Net Loss $7.7 Mln Vs. Net Loss $6.9 Mln Last Year
7/8/2022 7:03:46 AM
Precision Autoimmune Therapeutics Completes First-round Financing Of About $21 Mln
5/24/2022 7:11:00 AM
CASI Pharma Signs Sublicense Agreement With Beijing Tianshi
5/12/2022 7:17:49 AM
CASI Pharma Q1 Loss Per Share $0.06 Vs Loss $0.11 Last Year
3/28/2022 7:15:32 AM
CASI Pharma FY Net Loss $35.8 Mln Vs $47.5 Mln Last Year
3/4/2022 7:03:49 AM
CASI Pharma Enters Renewal Exclusive Distribution Agreement For Sale Of EVOMELA For Injection In China
2/16/2022 7:15:56 AM
CASI Pharma Expects To Report EVOMELA Q4 Revenue Of About $9.12 Mln
1/20/2022 7:09:07 AM
Casi Partner, Bioinvent, Announces Bi-1206 Granted Orphan Drug Designation By FDA For Follicular Lymphoma Treatment
1/18/2022 7:05:06 AM
CASI Pharma Says US FDA Grants Orphan Drug Designation To Its Partner Juventas Cell Therapy For CNCT19
1/3/2022 7:01:52 AM
Casi Pharma Receives Nasdaq Deficiency Notice
11/12/2021 7:03:54 AM
CASI Pharma Q3 Loss Per Share $0.07 Vs Loss $0.14 Last Year